KRBP

Kiromic BioPharma Announces Reverse Stock Split

Retrieved on: 
Friday, March 10, 2023

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time today, March 10, 2023.

Key Points: 
  • Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time today, March 10, 2023.
  • As a result of the reverse stock split, the CUSIP number for the Company’s common stock will now be 497634204.
  • Upon effectiveness of the reverse stock split, every 30 shares of Kiromic common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock.
  • Immediately after the reverse stock split becomes effective, the Company will have approximately 966,758 shares of common stock issued and outstanding.

Lifshitz Law PLLC Announces Investigations of FMIA, SUMO, KRBP, and HYRE

Retrieved on: 
Sunday, February 26, 2023

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SUMO to affiliates of Francisco Partners for $12.05 per share in cash.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SUMO to affiliates of Francisco Partners for $12.05 per share in cash.
  • Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with possible false and misleading statements to investors concerning commercial prospects for the company’s immunotherapy medications.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with possible false and misleading statements to investors concerning HYRE’s insurance reserves.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

KRBP 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys Before Oct. 4th Deadline in Securities Class Action

Retrieved on: 
Sunday, October 2, 2022

SAN FRANCISCO, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys Before Oct. 4th Deadline in Securities Class Action

Retrieved on: 
Tuesday, September 27, 2022

SAN FRANCISCO , Sept. 27, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .

Key Points: 
  • SAN FRANCISCO , Sept. 27, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

KRBP 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys Before Oct. 4th Deadline in Securities Class Action

Retrieved on: 
Thursday, September 22, 2022

SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

KRBP CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Pending

Retrieved on: 
Saturday, September 17, 2022

SAN FRANCISCO, Sept. 17, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Sept. 17, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

KRBP INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Retrieved on: 
Monday, September 12, 2022

SAN FRANCISCO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

KRBP DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Pending

Retrieved on: 
Tuesday, September 6, 2022

SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

KRBP CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Retrieved on: 
Monday, August 29, 2022

On July 16, 2021, two weeks after the closing of the ordering, Kiromic disclosed that it had received comments from the FDA on its two IND applications.

Key Points: 
  • On July 16, 2021, two weeks after the closing of the ordering, Kiromic disclosed that it had received comments from the FDA on its two IND applications.
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

KRBP LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Retrieved on: 
Monday, August 22, 2022

SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.